Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
Abstract
Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or
moderately hypofractionated regimens with respect to biochemical or clinical failure
in patients with localized prostate cancer is unclear.
Author
van As, Nicholas
Griffin, Clare
Tree, Alison
Patel, Jaymini
Ostler, Peter
van der Voet, Hans
Loblaw, Andrew
Chu, William
Ford, Daniel
Tolan, Shaun
Jain, Suneil
Camilleri, Philip
Kancherla, Kiran
Frew, John
Chan, Andrew
Naismith, Olivia
Armstrong, John
Staffurth, John
Martin, Alexander
Dayes, Ian
Wells, Paula
Price, Derek
Williamson, Emily
Pugh, Julia
Manning, Georgina
Brown, Stephanie
Burnett, Stephanie
Hall, Emma
Griffin, Clare
Tree, Alison
Patel, Jaymini
Ostler, Peter
van der Voet, Hans
Loblaw, Andrew
Chu, William
Ford, Daniel
Tolan, Shaun
Jain, Suneil
Camilleri, Philip
Kancherla, Kiran
Frew, John
Chan, Andrew
Naismith, Olivia
Armstrong, John
Staffurth, John
Martin, Alexander
Dayes, Ian
Wells, Paula
Price, Derek
Williamson, Emily
Pugh, Julia
Manning, Georgina
Brown, Stephanie
Burnett, Stephanie
Hall, Emma
Citations
Altmetric:
Date
2024
Type
Article
Other
Other
Subject
Collections
Citation
N. van As, C. Griffin, A. Tree, J. Patel, P. Ostler, H. van der Voet, A. Loblaw, W. Chu, D. Ford, S. Tolan, S. Jain, P. Camilleri, K. Kancherla, J. Frew, A. Chan, O. Naismith, J. Armstrong, J. Staffurth, A. Martin, I. Dayes, P. Wells, D. Price, E. Williamson, J. Pugh, G. Manning, S. Brown, S. Burnett, and E. Hall
Journal / Source Title
The New England Journal of Medicine
DOI
10.1056/NEJMoa2403365
PMID
39413377
Publisher
Massachusetts Medical Society
Publisher’s URL
DOI: 10.1056/NEJMoa2403365